instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Musculoskeletal disorder'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nervous system disorder'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory disorder'. | Efficacy and safety of levetiracetam as adjunctive therapy for refractory focal epilepsy.
Epilepsy affects about 50 million people worldwide and around 30% of these patients have refractory epilepsy, with potential consequences regarding quality of life, morbidity and premature mortality.
The aim of treatment with a... | LEVETIRACETAM, UNSPECIFIED INGREDIENT | DrugsGivenReaction | CC BY | 34133509 | 19,569,926 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal discomfort'. | Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.
Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance ... | AMLODIPINE BESYLATE, MYCOPHENOLATE MOFETIL, TACROLIMUS, VALSARTAN | DrugsGivenReaction | CC BY-NC | 34134605 | 20,149,898 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug intolerance'. | Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.
Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance ... | AMLODIPINE BESYLATE, MYCOPHENOLATE MOFETIL, TACROLIMUS, VALSARTAN | DrugsGivenReaction | CC BY-NC | 34134605 | 20,149,898 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tremor'. | Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.
Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance ... | AMLODIPINE BESYLATE, MYCOPHENOLATE MOFETIL, TACROLIMUS, VALSARTAN | DrugsGivenReaction | CC BY-NC | 34134605 | 20,149,898 | 2021-12 |
What is the weight of the patient? | Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.
Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance ... | 60 kg. | Weight | CC BY-NC | 34134605 | 20,149,898 | 2021-12 |
What was the dosage of drug 'AMLODIPINE BESYLATE'? | Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.
Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance ... | 1 DOSAGE FORM, OD | DrugDosageText | CC BY-NC | 34134605 | 20,149,898 | 2021-12 |
What was the dosage of drug 'MYCOPHENOLATE MOFETIL'? | Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.
Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance ... | 0.5 GRAM, BID | DrugDosageText | CC BY-NC | 34134605 | 20,149,898 | 2021-12 |
What was the dosage of drug 'VALSARTAN'? | Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.
Gut dysbiosis may be implicated in the pathogenesis of IgA nephropathy (IgAN) through immune and/or metabolite pathways. Fecal microbiota transplantation (FMT) could reestablish the micro-ecological balance ... | 1 DOSAGE FORM, OD | DrugDosageText | CC BY-NC | 34134605 | 20,149,898 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Euglycaemic diabetic ketoacidosis'. | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | INSULIN NOS, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34134652 | 20,219,481 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Foetal exposure during pregnancy'. | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | INSULIN NOS, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34134652 | 20,218,015 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypoglycaemia neonatal'. | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | INSULIN NOS, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34134652 | 20,218,015 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Live birth'. | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | INSULIN NOS, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34134652 | 20,219,481 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Maternal exposure during pregnancy'. | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | INSULIN NOS, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34134652 | 20,219,481 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'SARS-CoV-2 test positive'. | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | INSULIN NOS, METFORMIN HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34134652 | 20,219,481 | 2021-06-16 |
What was the administration route of drug 'INSULIN NOS'? | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | Transplacental | DrugAdministrationRoute | CC BY | 34134652 | 20,218,015 | 2021-06-16 |
What was the administration route of drug 'METFORMIN HYDROCHLORIDE'? | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | Transplacental | DrugAdministrationRoute | CC BY | 34134652 | 20,218,015 | 2021-06-16 |
What was the dosage of drug 'METFORMIN HYDROCHLORIDE'? | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | RESTARTED AFTER DELIVERY | DrugDosageText | CC BY | 34134652 | 20,219,481 | 2021-06-16 |
What was the outcome of reaction 'Euglycaemic diabetic ketoacidosis'? | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | Recovered | ReactionOutcome | CC BY | 34134652 | 20,219,481 | 2021-06-16 |
What was the outcome of reaction 'Foetal exposure during pregnancy'? | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | Recovered | ReactionOutcome | CC BY | 34134652 | 20,218,015 | 2021-06-16 |
What was the outcome of reaction 'Hypoglycaemia neonatal'? | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | Recovered | ReactionOutcome | CC BY | 34134652 | 20,218,015 | 2021-06-16 |
What was the outcome of reaction 'Live birth'? | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | Recovered | ReactionOutcome | CC BY | 34134652 | 20,219,481 | 2021-06-16 |
What was the outcome of reaction 'Maternal exposure during pregnancy'? | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | Recovered | ReactionOutcome | CC BY | 34134652 | 20,219,481 | 2021-06-16 |
What was the outcome of reaction 'SARS-CoV-2 test positive'? | Euglycaemic ketoacidosis in pregnant women with COVID-19: two case reports.
BACKGROUND
Euglycaemic ketoacidosis (EKA) is an infrequent but serious condition which usually follows a period of starvation, severe vomiting or illness in individuals with or without diabetes. Ketoacidosis is associated with materno-fetal mor... | Recovered | ReactionOutcome | CC BY | 34134652 | 20,219,481 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Apnoea'. | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | DESMOPRESSIN ACETATE, HYDROCORTISONE, HYDROMORPHONE, IBUPROFEN | DrugsGivenReaction | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Blood sodium decreased'. | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | DESMOPRESSIN ACETATE, HYDROCORTISONE, HYDROMORPHONE, IBUPROFEN | DrugsGivenReaction | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bruxism'. | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | DESMOPRESSIN ACETATE, HYDROCORTISONE, HYDROMORPHONE, IBUPROFEN | DrugsGivenReaction | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertonia'. | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | DESMOPRESSIN ACETATE, HYDROCORTISONE, HYDROMORPHONE, IBUPROFEN | DrugsGivenReaction | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Lethargy'. | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | DESMOPRESSIN ACETATE, HYDROCORTISONE, HYDROMORPHONE, IBUPROFEN | DrugsGivenReaction | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | DESMOPRESSIN ACETATE, HYDROCORTISONE, HYDROMORPHONE, IBUPROFEN | DrugsGivenReaction | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Potentiating drug interaction'. | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | DESMOPRESSIN ACETATE, HYDROCORTISONE, HYDROMORPHONE, IBUPROFEN | DrugsGivenReaction | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
What was the administration route of drug 'HYDROCORTISONE'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Oral | DrugAdministrationRoute | CC BY | 34134784 | 19,502,744 | 2021-06-16 |
What was the administration route of drug 'IBUPROFEN'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Oral | DrugAdministrationRoute | CC BY | 34134784 | 19,502,744 | 2021-06-16 |
What was the administration route of drug 'SOMATROPIN'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Subcutaneous | DrugAdministrationRoute | CC BY | 34134784 | 19,502,744 | 2021-06-16 |
What was the outcome of reaction 'Apnoea'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
What was the outcome of reaction 'Apnoeic attack'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 20,962,087 | 2021-06-16 |
What was the outcome of reaction 'Blood sodium decreased'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
What was the outcome of reaction 'Bruxism'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
What was the outcome of reaction 'Drug interaction'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 20,962,087 | 2021-06-16 |
What was the outcome of reaction 'Hypertonia'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
What was the outcome of reaction 'Hyponatraemia'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 19,502,744 | 2021-06-16 |
What was the outcome of reaction 'Lethargy'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
What was the outcome of reaction 'Off label use'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
What was the outcome of reaction 'Potentiating drug interaction'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 19,499,713 | 2021-06-16 |
What was the outcome of reaction 'Seizure'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 20,962,087 | 2021-06-16 |
What was the outcome of reaction 'Unresponsive to stimuli'? | Central diabetes insipidus and pain medications - a risky combination.
BACKGROUND
Central Diabetes Insipidus (CDI) results from decreased production of antidiuretic hormone (ADH) leading to an inability to concentrate urine. CDI is treated with desmopressin (DDAVP). Rarely reported in the literature, opioids and non-st... | Recovered | ReactionOutcome | CC BY | 34134784 | 20,962,087 | 2021-06-16 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug intolerance'. | Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review.
Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clini... | GEMCITABINE HYDROCHLORIDE, GIMERACIL\OTERACIL\TEGAFUR, OXALIPLATIN, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC | 34135598 | 19,567,194 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Toxicity to various agents'. | Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review.
Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clini... | GEMCITABINE HYDROCHLORIDE, GIMERACIL\OTERACIL\TEGAFUR, OXALIPLATIN, TRASTUZUMAB | DrugsGivenReaction | CC BY-NC | 34135598 | 19,567,194 | 2021 |
What was the administration route of drug 'GIMERACIL\OTERACIL\TEGAFUR'? | Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review.
Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clini... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34135598 | 19,567,194 | 2021 |
What was the administration route of drug 'OXALIPLATIN'? | Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review.
Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clini... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34135598 | 19,567,194 | 2021 |
What was the administration route of drug 'TRASTUZUMAB'? | Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review.
Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clini... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34135598 | 19,567,194 | 2021 |
What was the dosage of drug 'GEMCITABINE HYDROCHLORIDE'? | Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review.
Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clini... | UNK UNK, QW | DrugDosageText | CC BY-NC | 34135598 | 19,567,194 | 2021 |
What was the dosage of drug 'GEMCITABINE\GEMCITABINE HYDROCHLORIDE'? | Durable Clinical Response to Immune and Targeted Therapies in an Elderly Man with Synchronous Gastric (HER2+) and Bladder Cancers: Case Report and Literature Review.
Synchronous occurrences of gastric cancer positive for human epidermal growth factor receptor 2 (HER2+) and bladder cancer are rarely encountered in clini... | ONCE?WEEKLY | DrugDosageText | CC BY-NC | 34135598 | 19,495,553 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cytomegalovirus infection'. | Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study.
Objective: This study aimed to investigate epidemiological characteristics, clinical manifestations, and long-term outcomes of patients with autoimmune encephalitis (AE) in the east of China. Methods: From January 2015 ... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, RITUXIMAB | DrugsGivenReaction | CC BY | 34135845 | 20,192,970 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Herpes simplex'. | Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study.
Objective: This study aimed to investigate epidemiological characteristics, clinical manifestations, and long-term outcomes of patients with autoimmune encephalitis (AE) in the east of China. Methods: From January 2015 ... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, RITUXIMAB | DrugsGivenReaction | CC BY | 34135845 | 20,192,970 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm'. | Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study.
Objective: This study aimed to investigate epidemiological characteristics, clinical manifestations, and long-term outcomes of patients with autoimmune encephalitis (AE) in the east of China. Methods: From January 2015 ... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, RITUXIMAB | DrugsGivenReaction | CC BY | 34135845 | 20,192,970 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pneumonia'. | Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study.
Objective: This study aimed to investigate epidemiological characteristics, clinical manifestations, and long-term outcomes of patients with autoimmune encephalitis (AE) in the east of China. Methods: From January 2015 ... | AZATHIOPRINE, CYCLOPHOSPHAMIDE, METHYLPREDNISOLONE, MYCOPHENOLATE MOFETIL, RITUXIMAB | DrugsGivenReaction | CC BY | 34135845 | 20,192,970 | 2021 |
What was the administration route of drug 'METHYLPREDNISOLONE'? | Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study.
Objective: This study aimed to investigate epidemiological characteristics, clinical manifestations, and long-term outcomes of patients with autoimmune encephalitis (AE) in the east of China. Methods: From January 2015 ... | Intravenous drip | DrugAdministrationRoute | CC BY | 34135845 | 20,192,970 | 2021 |
What was the dosage of drug 'METHYLPREDNISOLONE'? | Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study.
Objective: This study aimed to investigate epidemiological characteristics, clinical manifestations, and long-term outcomes of patients with autoimmune encephalitis (AE) in the east of China. Methods: From January 2015 ... | INITIAL DOSE OF 1,000 OR 500 MG | DrugDosageText | CC BY | 34135845 | 20,192,970 | 2021 |
What was the outcome of reaction 'Neoplasm'? | Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study.
Objective: This study aimed to investigate epidemiological characteristics, clinical manifestations, and long-term outcomes of patients with autoimmune encephalitis (AE) in the east of China. Methods: From January 2015 ... | Fatal | ReactionOutcome | CC BY | 34135845 | 20,192,970 | 2021 |
What was the outcome of reaction 'Pneumonia'? | Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study.
Objective: This study aimed to investigate epidemiological characteristics, clinical manifestations, and long-term outcomes of patients with autoimmune encephalitis (AE) in the east of China. Methods: From January 2015 ... | Fatal | ReactionOutcome | CC BY | 34135845 | 20,192,970 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
Childhood cancer survivors (CCSs) who have undergone bone marrow transplantation with systemic chemotherapy and whole-body irradiation often experience impaired glucose tolerance with marked insulin resi... | BEZAFIBRATE, INSULIN NOS, METFORMIN HYDROCHLORIDE, PIOGLITAZONE | DrugsGivenReaction | CC BY | 34135866 | 20,302,126 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Glycosylated haemoglobin increased'. | Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
Childhood cancer survivors (CCSs) who have undergone bone marrow transplantation with systemic chemotherapy and whole-body irradiation often experience impaired glucose tolerance with marked insulin resi... | BEZAFIBRATE, INSULIN NOS, METFORMIN HYDROCHLORIDE, PIOGLITAZONE | DrugsGivenReaction | CC BY | 34135866 | 20,302,126 | 2021 |
What was the administration route of drug 'BEZAFIBRATE'? | Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
Childhood cancer survivors (CCSs) who have undergone bone marrow transplantation with systemic chemotherapy and whole-body irradiation often experience impaired glucose tolerance with marked insulin resi... | Oral | DrugAdministrationRoute | CC BY | 34135866 | 20,302,126 | 2021 |
What was the administration route of drug 'INSULIN NOS'? | Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
Childhood cancer survivors (CCSs) who have undergone bone marrow transplantation with systemic chemotherapy and whole-body irradiation often experience impaired glucose tolerance with marked insulin resi... | Subcutaneous | DrugAdministrationRoute | CC BY | 34135866 | 20,302,126 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal pain'. | Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Immunotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and pr... | GEMCITABINE, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34135884 | 20,703,062 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Abdominal tenderness'. | Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Immunotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and pr... | GEMCITABINE, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34135884 | 20,703,062 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Immunotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and pr... | GEMCITABINE, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34135884 | 20,703,062 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Immunotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and pr... | GEMCITABINE, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34135884 | 20,703,062 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neoplasm progression'. | Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Immunotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and pr... | GEMCITABINE, PEMBROLIZUMAB | DrugsGivenReaction | CC BY | 34135884 | 20,703,062 | 2021 |
What was the dosage of drug 'PEMBROLIZUMAB'? | Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature.
Immunotherapy with immune checkpoint inhibitors (ICIs), including programmed cell death protein-1 (PD-1) and pr... | UNK (200 MG EVERY 3 WEEKS) | DrugDosageText | CC BY | 34135884 | 20,703,062 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19 pneumonia'. | Characteristics and outcomes of five patients with COVID-19 and hematological malignancies.
Patients with hematological cancer are at major risk of developing infectious complication. The prevention and treatment of COVID-19 in these patients is challenging. This experience, with the limitation of a small number of pat... | CYCLOPHOSPHAMIDE, RITUXIMAB | DrugsGivenReaction | CC BY | 34136224 | 20,036,716 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Characteristics and outcomes of five patients with COVID-19 and hematological malignancies.
Patients with hematological cancer are at major risk of developing infectious complication. The prevention and treatment of COVID-19 in these patients is challenging. This experience, with the limitation of a small number of pat... | CYCLOPHOSPHAMIDE, RITUXIMAB | DrugsGivenReaction | CC BY | 34136224 | 20,143,626 | 2021-06 |
What was the outcome of reaction 'COVID-19 pneumonia'? | Characteristics and outcomes of five patients with COVID-19 and hematological malignancies.
Patients with hematological cancer are at major risk of developing infectious complication. The prevention and treatment of COVID-19 in these patients is challenging. This experience, with the limitation of a small number of pat... | Recovered | ReactionOutcome | CC BY | 34136224 | 20,036,716 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19'. | Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus.
A 61-year-old male on everolimus had chronic SARS-CoV-2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for CO... | EVEROLIMUS, LANREOTIDE, PEGINTERFERON ALFA-2A | DrugsGivenReaction | CC BY-NC | 34136234 | 20,305,440 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus.
A 61-year-old male on everolimus had chronic SARS-CoV-2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for CO... | EVEROLIMUS, LANREOTIDE, PEGINTERFERON ALFA-2A | DrugsGivenReaction | CC BY-NC | 34136234 | 20,305,440 | 2021-06 |
What was the administration route of drug 'EVEROLIMUS'? | Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus.
A 61-year-old male on everolimus had chronic SARS-CoV-2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for CO... | Oral | DrugAdministrationRoute | CC BY-NC | 34136234 | 20,305,440 | 2021-06 |
What was the administration route of drug 'LANREOTIDE'? | Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus.
A 61-year-old male on everolimus had chronic SARS-CoV-2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for CO... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34136234 | 20,305,440 | 2021-06 |
What was the administration route of drug 'PEGINTERFERON ALFA-2A'? | Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus.
A 61-year-old male on everolimus had chronic SARS-CoV-2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for CO... | Subcutaneous | DrugAdministrationRoute | CC BY-NC | 34136234 | 20,305,440 | 2021-06 |
What was the outcome of reaction 'COVID-19'? | Response to pegylated interferon in a COVID-19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus.
A 61-year-old male on everolimus had chronic SARS-CoV-2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for CO... | Recovered | ReactionOutcome | CC BY-NC | 34136234 | 20,305,440 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adrenocorticotropic hormone deficiency'. | Isolated adrenocorticotropin deficiency induced by pembrolizumab for hypopharyngeal cancer: A case report.
We report a case of isolated adrenocorticotropin deficiency caused by pembrolizumab. This condition can be fatal, but its rarity causes under-recognition. Oncologists should pay attention to adrenal insufficiency ... | PEMBROLIZUMAB | DrugsGivenReaction | CC BY-NC-ND | 34136239 | 19,943,657 | 2021-06 |
What was the administration route of drug 'PEMBROLIZUMAB'? | Isolated adrenocorticotropin deficiency induced by pembrolizumab for hypopharyngeal cancer: A case report.
We report a case of isolated adrenocorticotropin deficiency caused by pembrolizumab. This condition can be fatal, but its rarity causes under-recognition. Oncologists should pay attention to adrenal insufficiency ... | Intravenous drip | DrugAdministrationRoute | CC BY-NC-ND | 34136239 | 19,943,657 | 2021-06 |
What was the outcome of reaction 'Adrenocorticotropic hormone deficiency'? | Isolated adrenocorticotropin deficiency induced by pembrolizumab for hypopharyngeal cancer: A case report.
We report a case of isolated adrenocorticotropin deficiency caused by pembrolizumab. This condition can be fatal, but its rarity causes under-recognition. Oncologists should pay attention to adrenal insufficiency ... | Recovered | ReactionOutcome | CC BY-NC-ND | 34136239 | 19,943,657 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tendon disorder'. | A rare case of Levofloxacin-related Iliopsoas and Achilles tendon rupture.
Achilles tendon rupture is a well-documented adverse effect of Fluoroquinolones; however, herein we present a case of complete iliopsoas and Achilles, and partial semimembranosus tendon rupture secondary to Levofloxacin.
1 CASE PRESENTATION
A 7... | LEVOFLOXACIN, PREDNISONE | DrugsGivenReaction | CC BY-NC | 34136248 | 19,783,543 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tendon rupture'. | A rare case of Levofloxacin-related Iliopsoas and Achilles tendon rupture.
Achilles tendon rupture is a well-documented adverse effect of Fluoroquinolones; however, herein we present a case of complete iliopsoas and Achilles, and partial semimembranosus tendon rupture secondary to Levofloxacin.
1 CASE PRESENTATION
A 7... | LEVOFLOXACIN, PREDNISONE | DrugsGivenReaction | CC BY-NC | 34136248 | 19,813,717 | 2021-06 |
What was the outcome of reaction 'Tendon disorder'? | A rare case of Levofloxacin-related Iliopsoas and Achilles tendon rupture.
Achilles tendon rupture is a well-documented adverse effect of Fluoroquinolones; however, herein we present a case of complete iliopsoas and Achilles, and partial semimembranosus tendon rupture secondary to Levofloxacin.
1 CASE PRESENTATION
A 7... | Recovering | ReactionOutcome | CC BY-NC | 34136248 | 19,783,543 | 2021-06 |
What was the outcome of reaction 'Tendon rupture'? | A rare case of Levofloxacin-related Iliopsoas and Achilles tendon rupture.
Achilles tendon rupture is a well-documented adverse effect of Fluoroquinolones; however, herein we present a case of complete iliopsoas and Achilles, and partial semimembranosus tendon rupture secondary to Levofloxacin.
1 CASE PRESENTATION
A 7... | Recovering | ReactionOutcome | CC BY-NC | 34136248 | 19,813,717 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Febrile neutropenia'. | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | CYTARABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Herpes simplex'. | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | CYTARABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mouth haemorrhage'. | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | CYTARABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nutritional condition abnormal'. | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | CYTARABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Obstructive airways disorder'. | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | CYTARABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory tract oedema'. | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | CYTARABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Shock haemorrhagic'. | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | CYTARABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Stomatitis'. | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | CYTARABINE, ETOPOSIDE, MITOXANTRONE HYDROCHLORIDE | DrugsGivenReaction | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
What is the weight of the patient? | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | 34 kg. | Weight | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
What was the administration route of drug 'CYTARABINE'? | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | Intrathecal | DrugAdministrationRoute | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
What was the administration route of drug 'ETOPOSIDE'? | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | Intrathecal | DrugAdministrationRoute | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
What was the outcome of reaction 'Febrile neutropenia'? | Life-threatening oral mucositis following chemotherapy in a pediatric patient.
Severe oral mucositis as a complication of chemotherapy may lead to airway obstruction and require prolonged intubation. As its course is consistent with the course of neutropenia, airway management strategies should be determined individual... | Recovered | ReactionOutcome | CC BY-NC-ND | 34136255 | 19,821,048 | 2021-06 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.